Preclinical characterization of the Omicron XBB.1.5-adapted BNT162b2 COVID-19 vaccine
Sign Up to like & getrecommendations! Published in 2024 at "NPJ Vaccines"
DOI: 10.1038/s41541-024-01013-9
Abstract: As SARS-CoV-2 evolves, increasing in potential for greater transmissibility and immune escape, updated vaccines are needed to boost adaptive immunity to protect against COVID-19 caused by circulating strains. Here, we report features of the monovalent… read more here.
Keywords: xbb adapted; xbb; omicron xbb; adapted bnt162b2 ... See more keywords
P-2062. COVID-19 XBB.1.5-adapted Vaccine Uptake in Immunocompromised Individuals Using Tokenized State Vaccine Registries
Sign Up to like & getrecommendations! Published in 2025 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofae631.2218
Abstract: Abstract Background Immunocompromised individuals experience a disproportionate burden of COVID-19-associated hospitalization and death. COVID-19 vaccine uptake has declined over time. We evaluated XBB.1.5-adapted vaccine uptake, regardless of brand, during the 2023-2024 season among immunocompromised persons… read more here.
Keywords: pfizer inc; xbb adapted; vaccine uptake; pfizer ... See more keywords
Systemic and Mucosal Immunogenicity of Monovalent XBB.1.5-Adapted COVID-19 mRNA Vaccines in Patients with Inflammatory Bowel Disease
Sign Up to like & getrecommendations! Published in 2024 at "Vaccines"
DOI: 10.3390/vaccines12070774
Abstract: Recently updated COVID-19 mRNA vaccines encode the spike protein of the omicron subvariant XBB.1.5 and are recommended for patients with inflammatory bowel disease (IBD) on immunosuppressive treatment. Nonetheless, their immunogenicity in patients with IBD against… read more here.
Keywords: mucosal; xbb adapted; xbb; vaccination ... See more keywords